Revance Therapeutics, Inc.(RVNC)

Description: Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.

---

Keywords: Biopharmaceutical Drugs Pain Plastic Surgery Migraine Neuropathic Pain Headache Toxins Rhinitis Botulinum Toxin Therapeutic Applications Botulism Neurotoxins Migraine Headache Botulinum Toxin Products Hyperhidrosis

---

Home Page: www.revance.com

RVNC Technical Analysis

1222 Demonbreun Street
Nashville, TN 37203
United States
Phone: 615 724 7755

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)